Tumoren des Dünndarms

Oberhuber, Georg

doi:10.1007/978-3-642-02322-4_19

Cited by 9 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Initially termed GI carcinoid tumors by Oberndorfer in 1907 (67), these tumors show neuroendocrine differentiation and are now referred to as NETs. GI NET are generally indolent, but some can behave aggressively and metastasize.…”

Section: Treatment Of Subepithelial Lesionsmentioning

confidence: 99%

ACG Clinical Guideline: Diagnosis and Management of Gastrointestinal Subepithelial Lesions

et al. 2022

View full text Add to dashboard Cite

Subepithelial lesions (SEL) of the GI tract represent a mix of benign and potentially malignant entities including tumors, cysts, or extraluminal structures causing extrinsic compression of the gastrointestinal wall. SEL can occur anywhere along the GI tract and are frequently incidental findings encountered during endoscopy or cross-sectional imaging. This clinical guideline of the American College of Gastroenterology was developed using the Grading of Recommendations Assessment, Development, and Evaluation process and is intended to suggest preferable approaches to a typical patient with a SEL based on the currently available published literature. Among the recommendations, we suggest endoscopic ultrasound (EUS) with tissue acquisition to improve diagnostic accuracy in the identification of solid nonlipomatous SEL and EUS fine-needle biopsy alone or EUS fine-needle aspiration with rapid on-site evaluation sampling of solid SEL. There is insufficient evidence to recommend surveillance vs resection of gastric gastrointestinal stromal tumors (GIST) <2 cm in size. Owing to their malignant potential, we suggest resection of gastric GIST >2 cm and all nongastric GIST. When exercising clinical judgment, particularly when statements are conditional suggestions and/or treatments pose significant risks, health-care providers should incorporate this guideline with patient-specific preferences, medical comorbidities, and overall health status to arrive at a patient-centered approach.

show abstract

Section: Treatment Of Subepithelial Lesionsmentioning

confidence: 99%

ACG Clinical Guideline: Diagnosis and Management of Gastrointestinal Subepithelial Lesions

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Neuroendocrine tumors (NETs) in other body sites have been recognized to show a spectrum of behavior that varies from indolent to aggressive. As an example, small bowel NETs were initially called ‘carcinoid’ (meaning ‘carcinoma-like’) because they were described by Oberndorfer as lesions that looked like but were not carcinomas ( Oberndorfer 1907 ). Subsequent evidence required a change in our understanding of these lesions that clearly have metastatic potential.…”

Section: Current Definitionsmentioning

confidence: 99%

Pituitary carcinoma: reclassification and implications in the NET schema

Sylvia

Ezzat

2022

Endocrine Oncology

View full text Add to dashboard Cite

The entity known as pituitary carcinoma has been traditionally defined as a tumor of adenohypophysial cells that metastasizes systemically or craniospinally independent of the histological appearance of the lesion. Reported cases of pituitary carcinoma have clinically and histologically resembled their non-metastatic counterparts that were classified as adenomas; the majority of cases were initially diagnosed as adenomas, and with tumor progression and spread, the diagnosis was changed to carcinoma. This classification has been challenged since the definition of malignancy in most organs is not based only on metastatic spread. The extent of local invasion resulting in an inability to completely resect an adenohypophysial tumor can have serious consequences that can cause harm and are therefore not benign. To address this dilemma, it was proposed that pituitary tumors be classified as neuroendocrine tumors. This change in nomenclature is totally appropriate since these tumors are composed of classical neuroendocrine cells; as with other neuroendocrine tumors, they have variable behavior that can be indolent but can involve metastasis. With the new nomenclature there is no requirement for a distinction between adenomas and carcinomas. Moreover, the WHO/IARC has provided an overarching classification for neuroendocrine neoplasms at all body sites; in this new classification, the term 'neuroendocrine carcinoma' is reserved for poorly-differentiated high-grade malignancies that are clinically, morphologically and genetically distinct from well differentiated neuroendocrine tumors. It remains to be determined if there are true pituitary neuroendocrine carcinomas.

show abstract

“…/Literature Review/ Нейроендокринні пухлини (НЕП) -це досить різноманітна група новоутворень, що беруть початок від нейроендокринних клітин, поширених практично по всіх частинах тіла. У далекому 1902 році Obendorfer вперше застосував поняття «карциноїд» [1]; наприкінці 1970-х років Пірс подав концепцію спеціалізованої високоорганізованої клітинної системи, яку назвав APUD-системою (Amine Precursor Uptake and Decarboxylation) [2,3]. НЕП здатні продукувати пептиди, що викликають типові гормональні синдроми.…”

Section: огляд літературиunclassified

“…У клінічній практиці для визначення НЕП шлунково-кишкового тракту (ШКТ) до цього часу використовують декілька синонімів. Obendorfer запропонував термін «карциноїд» для назви інтестинальних пухлин із менш агресивним, ніж в аденокарцином, клінічним перебігом [1]. Ендокринна природа цих пухлин була доведена Мерлінгом у 1938 р.…”

Section: огляд літературиunclassified

Нейроэндокринные Опухоли: Аспекты Диагностики (Обзор Литературы)

Kvachenyuk¹

2021

Mìžnarodnij endokrinologìčnij žurnal

View full text Add to dashboard Cite

В работе проведен анализ литературных источников по проблеме ведения больных с нейроэндокринными опухолями как в историческом ракурсе, так и в современном аспекте. Особое внимание уделено классификациям, клинико-диагностическим и лабораторно-диагностическим этапам ведения пациента с нейроэндокринными опухолями, особенно исследованию биологических маркеров.

show abstract

Tumoren des Dünndarms

Cited by 9 publications

References 35 publications

ACG Clinical Guideline: Diagnosis and Management of Gastrointestinal Subepithelial Lesions

ACG Clinical Guideline: Diagnosis and Management of Gastrointestinal Subepithelial Lesions

Pituitary carcinoma: reclassification and implications in the NET schema

Нейроэндокринные Опухоли: Аспекты Диагностики (Обзор Литературы)

Contact Info

Product

Resources

About